LivaNova PLC (NASDAQ: LIVN) announced the election of Jette Nygaard-Andersen to its Board of Directors following the company's Annual General Meeting on June 10.

Nygaard-Andersen brings more than 25 years of leadership experience in regulated international businesses. She currently serves as Chair of the Board for Coloplast A/S, a Denmark-based medical device company, and has held that non-executive director role since 2015.

Her executive background includes serving as Chief Executive Officer of Entain plc, a sports betting and gaming company, and spending 16 years at Modern Times Group AB, where she held various senior positions including Chief Operating Officer and CEO of multiple business units. She holds a Master of Science degree in Business Administration with a concentration in Finance from the University of Copenhagen.

The appointment coincides with Dr. Sharon O'Kane stepping down from the board after deciding not to seek re-election. O'Kane had served as a board member for 10 years since LivaNova's formation in 2015.

The company also announced several committee leadership changes. Brooke Story, appointed to the board in 2022, will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee. Peter Wilver will assume the position of Chair of the Compensation and Human Capital Management Committee, replacing Stacy Enxing Seng. Todd Schermerhorn will remain Chair of the Audit and Compliance Committee.

LivaNova is a medical technology company headquartered in London with approximately 3,300 employees and operations in more than 100 countries. The company focuses on neurological and cardiac medical solutions.